Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

From overfilling to the wrong shape, most brow routines need a refresh. This video shows how to bring your brow game up to date with subtle corrections and smart tools that make a visible difference.

In a report released today, Peter Lawson from Barclays maintained a Hold rating on Replimune Group, with a price target of $3.00. The company’s shares closed yesterday at $8.95. Take advantage of ...

Replimune Group (REPL) has drawn attention after presenting updated clinical data from its IGNYTE phase 2 trial at the ESMO Congress 2025. The study combined RP1 with nivolumab in patients with acral ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 92,988 contracts has ...